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Abstract
BACKGROUND—Our objective was to determine how patient preferences guide the course of
palliative chemotherapy for advanced colorectal cancer.
METHODS—Eligible patients with metastatic colorectal cancer (mCRC) were enrolled
nationwide in a prospective, population-based cohort study. Data were obtained via medical
record abstraction and patient surveys. Logistic regression was used to evaluate: patient
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characteristics associated with seeing medical oncology and receiving chemotherapy; and patient
characteristics, beliefs and preferences associated with receiving >1 line of chemotherapy and
receiving combination chemotherapy.
RESULTS—Among 702 patients with mCRC, 91% saw a medical oncologist, and among those,
82% received chemotherapy. Patients 65-75 and ≥75 years were less likely to see an oncologist, as
were patients who were too sick to complete their own survey. In adjusted analyses patients ≥75
years and with moderate or severe comorbidity were less likely to receive chemotherapy, as were
patients who were too sick to complete their own survey. Patients received chemotherapy even if
they believed chemotherapy would not extend their life (90%), chemotherapy would not likely
help with cancer-related problems (89%), or preferred treatment focusing on comfort even if it
meant not living as long (90%). Older patients were less likely to receive combination first-line
therapy. Patient preferences and beliefs were not associated with receipt of >1 line of
chemotherapy or combination chemotherapy.
CONCLUSIONS—The majority of patients received chemotherapy even if they expressed
negative or marginal preferences or beliefs regarding chemotherapy. Patient preferences and
beliefs were not associated with intensity or number of chemotherapy regimens.
Keywords
Colorectal cancer; decision making; patient preference; cohort studies; quality of healthcare
BACKGROUND
A growing body of evidence has demonstrated the value of patient-centered care. Patients
involved in decision-making are more knowledgeable about their care and more satisfied
with their care.1, 2 Patient dissatisfaction with treatment-related decision-making may
negatively impact the quality of cancer care.3 Patient preferences should be particularly
emphasized in the setting of advanced cancer, where the treatment is palliative. For
example, while chemotherapy for patients with advanced colorectal cancer can modestly
extend survival, it is associated with risk of significant toxicity.4 This balance between
possible benefit versus probable risk necessitates a patient-centered approach to treatment
decision-making. However, studies suggest improper use of chemotherapy near the end of
life may reflect inadequate shared decision-making between patient and physician.5
Physicians may find it easier to offer chemotherapy for the patient with advanced cancer
rather than engaging in challenging end-of-life discussions.6 For their part, patients might
prefer to take a passive decision-making role when considering therapy for advanced
cancer.7, 8 What remains unclear is how patient preferences guide the course of palliative
chemotherapy for advanced cancer.
To evaluate the quality of patient-centered care for patients with advanced cancer, an
important question must be answered: do patient preferences play a role in treatment-related
decision-making for palliative chemotherapy? We conducted a multiregional cohort study of
patients with advanced colorectal cancer to assess factors associated with seeing a medical
oncologist and receipt of chemotherapy, specifically addressing the effect of the patient’s
role in decision-making, quality of communication with their physician, overall quality of
care, preferences for treatment, and their beliefs and concerns regarding treatment. We
hypothesized that patient preferences would play a role in treatment-related decision-
making.
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Study participants were enrolled by the Cancer Care Outcomes Research and Surveillance
(CanCORS) Consortium. CanCORS is a prospective, observational, population- and
healthcare systems-based cohort study to determine how characteristics and beliefs of cancer
patients, providers, and health care organizations influence treatments and outcomes.9
Patients 21 years or older with colorectal cancer were enrolled from one of the following:
five geographic regions, five integrated health care systems in the NCI-funded Cancer
Research Network, or fifteen Veterans Administration (VA) Hospitals from September,
2003 to January, 2006 within three months of diagnosis. Patients were followed for 15
months past enrollment. Only patients with stage IV colorectal cancer (n=702) were
included in this analysis.
Data collection
Primary data were collected from medical records, patient surveys, and surrogate
surveys.9-11 Trained abstractors at each of the data-collection sites abstracted medical
records data, including cancer diagnosis, initial tumor location, and stage. Medical record
data were also used to verify medical oncology visits, determine the first line of
chemotherapy delivered (defined as the first chemotherapy regimen used to treat the
patient’s metastatic colorectal cancer), and determine whether the first line of therapy was
single agent or combination therapy (more than one chemotherapeutic agent). Comorbidity
was abstracted from the medical record and scored using the Adult Comorbidity Evaluation
27 (ACE-27), a 27-item index developed to provide prognostic information for cancer
patients.12
Patient surveys were completed in English, Chinese, and Spanish using computer-assisted
telephone interviews. A surrogate (relative or household member) familiar with the patient’s
cancer care was interviewed for patients who had died or were too ill to be interviewed. The
surveys (available at www.cancors.org/public) used previously validated items and scales
whenever possible and assessed patients’ sociodemographic characteristics (age, race/
ethnicity, annual income), insurance coverage, comorbid conditions, and beliefs about
cancer care; survey development has been previously described.11 Surveys also assessed
quality of communication with their physician (5 items),11 overall quality of care (2 items),
preferences for treatment (2 items), and beliefs and concerns regarding treatment (9
items).13 For patients who were too ill (n=60) or had died (n=140), a survey was
administered to a surrogate when available. Most patients completed the survey after
treatment was started. Human subject committees approved the study protocol at each
participating site.
Statistical analysis
We calculated descriptive statistics summarizing sociodemographic characteristics,
comorbidity, treatment, and survey-based patient preferences and beliefs. We used logistic
regression to assess factors associated with seeing a medical oncologist and receipt of
chemotherapy. Four analytic models were developed to assess factors associated with: (1)
seeing a medical oncologist anytime prior to survey completion; (2) receipt of
chemotherapy; (3) receipt of combination vs. single-agent first-line therapy; and (4) receipt
of only one vs. more than one lines of therapy. In models 3 and 4 we considered the
variables addressing role in chemotherapy decision-making, quality of communication with
their physician, overall quality of care, preferences for treatment, and beliefs and concerns
regarding treatment. These variables were not included in model 1 since not all of those
patients completed a survey. These variables were not included in model 2 since they are
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available only for patients seeing an oncologist and completing full surveys (n=409). Among
patients completing a full survey, only 23 patients did not receive chemotherapy. An
effective sample of 23 was too small to produce reliable results in logistic regression.
A consistent model building approach was used for all outcomes. Four variables were
included unconditionally in all models: age, comorbidity, gender, and race. Survey
respondent (patient vs. surrogate) was included as a variable in models 1 and 2. Step-wise
model refinement was applied with p=0.20 criterion for entering variables into the models
and p=0.10 criterion for removing them from the models. If necessary to prevent overfitting,
the least significant variables were removed to attain model degrees of freedom to effective
sample size ratio of ≥714. Multiple imputation was used to address item nonresponse for
survey-based variables and was performed centrally by the CanCORS Statistical
Coordinating Center.15 Results from multivariable models incorporate formal imputation
adjustments.16
Data analysis was conducted at the Durham VA Medical Center, the coordinating site for
VA hospitals participating in CanCORS. This analysis used CanCORS core data (version
1.9), medical record data (version 1.9), and patient survey data (version 1.8). Statistical
analyses were performed using SAS for Windows Version 9.2 (SAS Institute, Cary, NC).
RESULTS
Cohort characteristics
Seven hundred two patients were included in this analysis (Figure 1). Patient characteristics
are summarized in Table 1.
Medical oncology visits
Ninety-one percent of 702 patients had at least one visit with a medical oncologist (n=640,
Figure 1). In multivariable analysis (Figure 2), age was associated with seeing an oncologist:
patients 65-74 years old and ≥75 years old were less likely than those <55 years old to see
an oncologist. Survey type (self-completion vs. completion by a surrogate) was significantly
associated with seeing a medical oncologist, reflecting the greater severity of illness and
functional decline among patients who were unable to fully participate in the survey.
Patients who had their surveys completed by a surrogate or patients without any survey data
were less likely to see a medical oncologist than patients who completed their own surveys.
Variables addressing role in chemotherapy decision-making, quality of communication with
their physician, overall quality of care, preferences for treatment, and beliefs and concerns
regarding treatment were not included in this model since they are available only for patients
seeing an oncologist and completing full surveys (n=409).
Chemotherapy regimens
Of those who consulted an oncologist (n=640), 527 (82%) received chemotherapy. Figure 3
illustrates the most common first-, second-, and third-line chemotherapy regimens. For their
first-line chemotherapy regimen, 32% of patients received only single-agent therapy (e.g.,
fluorouracil or capecitabine). Among 477 patients with available chemotherapy regimen
data, 63% received more than one line of chemotherapy. The regimens used for first-line
therapy were generally in concordance with those listed in the National Comprehensive
Cancer Network’s colorectal cancer guidelines between 2003-2006, the period inclusive of
patient enrollment.
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Unadjusted analyses are presented (Table 2). Among those seeing an oncologist, patients
who reported a preference for extending their life were more likely to receive chemotherapy
than those focusing on comfort (99% vs. 90%, p<0.001). Patients who believed
chemotherapy would extend their life were more likely to receive chemotherapy than those
who thought it unlikely that chemotherapy would extend their life (99% vs. 90%, p=0.008).
Patients who believed that chemotherapy might help with cancer-related problems were
more likely to receive chemotherapy than those who thought chemotherapy would be
unlikely to help (100% vs. 89%, p<0.001).
In multivariable analysis (Figure 4) age, comorbidity, and survey respondent were
significantly associated with receipt of chemotherapy. The oldest patients (age ≥75 years)
were least likely to receive chemotherapy when compared to those <55 years old. Patients
with moderate or severe comorbidity were less likely to receive chemotherapy than those
with no comorbidity. Patients who had their surveys completed by a surrogate were less
likely than patients who completed their own surveys to receive chemotherapy. Patients
without any survey data had a similarly lower likelihood of receiving chemotherapy.
Variables addressing role in chemotherapy decision-making, quality of communication with
their physician, overall quality of care, preferences for treatment, and beliefs and concerns
regarding treatment were not included in this model since they are available only for patients
seeing an oncologist and completing full surveys (n=409). Among this group only 23
patients did not receive chemotherapy; the effective sample of n=23 would have been too
small to produce reliable results in logistic regression models.
Intensity of first-line chemotherapy
Multivariable analysis examined the association between characteristics, preferences, beliefs
and intensity of first-line chemotherapy, as defined by receipt of combination therapy (more
than one drug) versus single-agent therapy (Figure 5). The oldest patients were less likely to
receive combination therapy as a part of their first-line regimen. Role in decision-making,
quality of communication with their physician, overall quality of care, preferences for
treatment, beliefs, and concerns regarding treatment were assessed but were not significantly
associated with receipt of combination first-line therapy.
Number of chemotherapy regimens
Multivariable analysis examined the association between characteristics, preferences, beliefs
and number of chemotherapy regimens received. Patient characteristics, role in decision-
making, quality of communication with their physician, overall quality of care, preferences
for treatment, beliefs, and concerns regarding treatment were assessed, but none were
significantly associated with receipt of combination first-line therapy (data not shown).
DISCUSSION
Given the substantial toxicity and personal costs associated with modest survival gains from
metastatic colorectal cancer treatment, we hypothesized patient preferences would play an
important role in receipt of palliative chemotherapy. We found patients with beliefs and
preferences favoring chemotherapy were statistically more likely to receive treatment.
Nonetheless, the vast majority of patients who expressed a preference for comfort-oriented
care believed that chemotherapy would be unlikely to extend their life, or did not believe
that chemotherapy would help with cancer-related problems still received chemotherapy.
Patient preferences, beliefs, concerns about treatment, actual and preferred role in decision-
making, and the quality of communication with their physician were not associated with
intensity or number of chemotherapy regimens delivered.
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Patient preference in palliative chemotherapy decision-making
Why did the majority of patients receive chemotherapy despite reporting beliefs and
preferences that would seem incongruent with this treatment choice? Patients who offered
negative or marginal views about chemotherapy in our survey might have still elected to
receive treatment in the hopes that they fall in the group of patients who experience a
meaningful benefit with minimal harm. This sense of optimism might have played a role in
our findings since patients who were a “little likely” to expect benefit might have considered
the risks of treatment reasonable. Patients with advanced cancer are often more willing than
their providers to accept greater risk of harm for smaller benefit.17 In addition, patients
might disregard their own negative views of treatment if they are in conflict with their
doctor’s view.3, 18, 19
In the metastatic setting where the benefit of treatment is limited, patients may be more
likely to defer treatment decision-making to their physician.7 Hence, clinical factors rather
than patient preference appear to have a disproportionate role in the treatment decision-
making process. Our study indeed suggests that clinical factors, in particular age and
comorbidity, influence the receipt of chemotherapy. These findings are consistent with a
substantial body of literature showing that older, sicker patients are less likely to receive
chemotherapy,17, 20-23 including the analysis by Kahn et al which focused on stage III
colorectal cancer patients enrolled in the same study described here.10 Furthermore,
completion of the survey by a surrogate rather than the patient likely serves as a proxy for
poor performance status.10 We found that completion of a surrogate survey was negatively
associated with seeing a medical oncologist, receiving any chemotherapy, and receiving
more than one line of chemotherapy. Older patients diagnosed with metastatic colorectal
cancer had lower odds of being referred to a medical oncologist. While older patients are at
higher risk of being diagnosed with colorectal cancer, our cohort includes patients who have
already been diagnosed. Furthermore, our model adjusted for comorbidity, race, and gender.
Hence, age remains an independent predictor of referral to medical oncology.
Appropriateness of palliative chemotherapy use
Multiple studies suggest underuse of adjuvant chemotherapy for stage III colorectal
cancer.10, 21, 23-27 Though the same degree of evidence is not available for the palliative
setting in the US, though several studies have described low rates of palliative chemotherapy
use for advanced colorectal cancer outside the U.S.28-32 However, appropriate use of
palliative chemotherapy for advanced cancer is difficult to discern without detailed clinical
information. Since guidelines do not recommend treatment of patients with poor
performance status, some patients are not candidates for chemotherapy from the time of
diagnosis. Our analysis does not suggest an underuse of chemotherapy for advanced
colorectal cancer in the U.S. We found that among patients who reported a preference for
chemotherapy or favored quantity over quality of life, virtually all received chemotherapy.
Additionally, the first-line chemotherapy regimens prescribed were largely those included in
clinical guidelines available at the time of data collection. Taken together, these data suggest
concerns regarding potential underuse of chemotherapy in patients with metastatic colorectal
cancer can largely be put to rest.
Our findings are subject to limitations. We were unable to model the association between
preferences, beliefs, and receipt of chemotherapy due to small effective sample sizes.
However, unadjusted results are presented and are informative. Additionally, we assessed
associations between those variables, intensity of chemotherapy, and number of lines of
chemotherapy. We did not collect data detailing the conversation between patient and
provider, so we cannot determine how that conversation might have colored patient
preferences or beliefs about chemotherapy. Most patients completed the survey after their
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treatment decisions had been made. Their preferences or beliefs might have been different if
measured prior to treatment decision-making. However, over the course of cancer care,
patient preferences tend to shift in favor of treatment,33 and the majority of patients who
expressed negative opinions towards chemotherapy still received treatment. Furthermore, we
were unable to assess the impact of online, print, nursing, or navigation resources in patient
decision-making. We did not focus on the use of chemotherapy at the very end of life and
cannot comment on overuse in that setting, as has been extensively reported in the
literature.5 Our data were collected between 2003-2006, and the focus on shared decision-
making has evolved over time. Finally, some survey items pertaining to preference and
beliefs were created specifically for CanCORS. Their validity has not been tested, but the
survey tool was thoroughly piloted.11
This study has several strengths. Our analyses are supported by both medical record and
patient self-reported data. Patients were enrolled from multiple geographic regions and
health care settings, and few exclusion criteria were applied. Patients enrolled in CanCORS
have been shown to be demographically representative of the geographic regions in which
they were enrolled.34
In summary, treatment decisions in the palliative setting were not always congruent with
stated preferences and beliefs regarding chemotherapy. The vast majority of patients who
expressed negative or marginal preferences or beliefs regarding chemotherapy still received
chemotherapy. Patient preferences and beliefs were not associated with intensity or number
of chemotherapy regimens delivered. Additionally, underuse of palliative chemotherapy was
not evident. These findings shed new light on the patient experience and decision-making in
the use of palliative chemotherapy, and can shift the focus of health services research in
advanced cancer from investigating underuse of treatment to the inclusion of patient
preferences in decision-making. Research should focus on tailoring delivery of care based
on patient preferences and beliefs.
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Derivation of study cohort. Of the 640 who met with a medical oncologist, 409 completed a
full patient survey. Of those who completed a full survey, only 23 patients did not receive
chemotherapy.
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Factors associated with seeing a medical oncologist (n=702).
CL, confidence limit; OR, adjusted odds ratio; LCL, lower confidence limit; UCL, upper
confidence limit
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Chemotherapy regimens used in the first, second, and third lines.
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Factors associated with receipt of chemotherapy (n=635; 4 insurance and 1 race values with
insufficient data).
CL, confidence limit; OR, adjusted odds ratio; LCL, lower confidence limit; UCL, upper
confidence limit
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Factors associated with receipt of combination chemotherapy vs. single-agent first-line
therapy (n=271; 116 with insufficient data regarding chemotherapy regimens).
CL, confidence limit; OR, adjusted odds ratio; LCL, lower confidence limit; UCL, upper
confidence limit
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 <55 170 24
 55-64 168 24
 65-74 178 25
 ≥75 186 27
ACE-27 Comorbidity Index (score)
 None (0) 221 32
 Mild (1) 265 38
 Moderate (2) 126 18
 Severe (3) 90 13
Race
 Unknown 1 <1
 Non-white 274 39
 White 427 61
Gender
 Female 268 38
 Male 434 62
Insurance
 Missing 38 5
 Public 103 15
 Medicare + Supplemental 209 30
 Veterans Administration 117 17
 Private 235 34
Geographic region
 West/Midwest 421 60
 South 146 21
 Atlantic 135 19
Health system
 Fee-for-Service 420 60
 Integrated health system 282 40
Survey respondent
 Survey completed by patient 441 63
 Survey completed by patient surrogate 200 29
 Survey not completed 61 9
Primary tumor site
 Missing 7 1
 Colon 528 75
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Characteristic n %*
 Rectum 142 20
 Colorectal 25 4
*
Percents might not sum to 100 due to rounding.
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